While incretin mimetics all suggest promising improvements in insulin sensitivity, BMI, and body weight for patients with PCOS, the exact mechanism behind how these medications affect dysmenorrhea and androgen imbalance associated with PCOS is unclear. Here, INS is linked to polycystic ovary syndrome.